Medical Company Announces Preferred Stock Acquisition: New CEO Invests $3M

In an ambitious move that could significantly alter its trajectory, OpGen, Inc., a key player in the precision medicine industry based in Rockville, Maryland, has announced a strategic shift that puts private investor David Lazar at the helm as the new CEO. This development follows Lazar's substantial investment of $3 million in preferred stock of the company. This article delves into the nuances of this deal, its implications for OpGen, and why it matters to investors and the biotech industry at large. $OpGen (OPGN.US)$